Testing a new drug for safety in prostate cancer patients
Official title: Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients with Prostate Cancer
Funded at Washington University · NIH-10978965 · Data updated 2026-11-12
This study is looking at a new drug called (R)-9b to see if it's safe and how well it works for men with advanced prostate cancer that hasn't responded to other treatments, and it hopes to help boost the immune system to fight the cancer better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | August 15, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $652,414 |
| NIH project number | 1R01CA286443-01A1 |
| Project ID | NIH-10978965 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have developed resistance to current therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not yet undergone treatment may not benefit from this research.
What this research studies
This research investigates the safety and tolerability of a new drug called (R)-9b, designed to inhibit a specific protein (ACK1) that plays a role in prostate cancer progression. The study will involve patients with advanced prostate cancer who have not responded to standard treatments. Participants will receive the drug and be monitored for any side effects, as well as for its ability to activate the immune system against cancer cells. The research aims to provide insights into how this new treatment could improve outcomes for patients with resistant forms of prostate cancer.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option that enhances the immune response against prostate cancer, potentially improving survival rates.
How similar studies have gone: Other research has shown promising results with similar approaches targeting immune modulation in cancer treatment, suggesting potential for success in this novel application.
Where this research is happening
-
Washington University
Saint Louis, United States Active
Researchers
- Principal investigator: Mahajan, Nupam P — Washington University
- Study coordinator: Mahajan, Nupam P
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.